Lisata Therapeutics, Inc.
DE ˙ DB ˙ US1280583022
2,92 € ↑0,12 (4,29%)
2026-06-04
DEL PRIS
SecurityDE:8NE / Lisata Therapeutics, Inc.
InstitutionRenaissance Technologies Llc
ManagerJames Simons
Latest Disclosed Ownership131,715 shares
Latest Disclosed Value $ 659,892
Renaissance Technologies Llc reports 6.47% increase in ownership of 8NE / Lisata Therapeutics, Inc.

On May 14, 2026 - Renaissance Technologies Llc filed a 13F-HR form disclosing ownership of 131,715 shares of Lisata Therapeutics, Inc. (DE:8NE) valued at $563,740 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 123,715 shares of Lisata Therapeutics, Inc.. This represents a change in shares of 6.47% during the quarter. The current value of the position is $384,608 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F LISATA THERAPEUTICS COM 128058302 131,715 8,000 6.47 660 186.52 0.0010
2026-02-12 2025-12-31 13F LISATA THERAPEUTICS COM 128058302 123,715 7,093 6.08 230 -24.59 0.0004
2025-11-13 2025-09-30 13F LISATA THERAPEUTICS COM 128058302 116,622 13,800 13.42 306 2.35 0.0004
2025-08-13 2025-06-30 13F LISATA THERAPEUTICS COM 128058302 102,822 100 0.10 298 23.65 0.0004
2025-05-14 2025-03-31 13F LISATA THERAPEUTICS COM 128058302 102,722 1,400 1.38 241 -19.93 0.0004
2025-02-13 2024-12-31 13F LISATA THERAPEUTICS COM 128058302 101,322 -2,300 -2.22 302 -2.90 0.0004
2024-11-13 2024-09-30 13F LISATA THERAPEUTICS COM 128058302 103,622 2,000 1.97 311 -11.93 0.0005
2024-08-09 2024-06-30 13F LISATA THERAPEUTICS COM 128058302 101,622 2,100 2.11 353 0.0006
2024-05-13 2024-03-31 13F LISATA THERAPEUTICS COM 128058302 99,522 2,300 2.37 0 0.0005
2024-02-13 2023-12-31 13F LISATA THERAPEUTICS COM 128058302 97,222 1,500 1.57 0 0.0004
2023-11-14 2023-09-30 13F LISATA THERAPEUTICS COM 128058302 95,722 2,400 2.57 0 0.0003
2023-08-11 2023-06-30 13F LISATA THERAPEUTICS COM 128058302 93,322 900 0.97 0 0.0005
2023-05-12 2023-03-31 13F LISATA THERAPEUTICS COM 128058302 92,422 300 0.33 0 0.0004
2023-02-13 2022-12-31 13F LISATA THERAPEUTICS COM 128058302 92,122 -8,800 -8.72 0 -100.00 0.0003
2022-11-14 2022-09-30 13F LISATA THERAPEUTICS COM 128058302 100,922 100,922 467 0.0007
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.